Standard Biotools (LAB) Accumulated Expenses (2010 - 2026)

Standard Biotools (LAB) has 17 years of Accumulated Expenses data on file, last reported at $1.7 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 14.48% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 14.48% increase from a year earlier, with the FY2025 full-year figure at $29.8 million, up 1783.81% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.7 million, down from $29.8 million in the prior quarter.
• Over the last five years, Accumulated Expenses for LAB reached as high as $31.7 million in Q3 2024 and fell as low as $825000.0 in Q4 2023.
• Historically, Accumulated Expenses has averaged $9.3 million across 5 years, with a median of $6.7 million in 2022.
• Across the five-year window, Accumulated Expenses sank 91.27% in 2023 and soared 3314.44% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $1.2 million in 2022, then slipped by 29.49% to $825000.0 in 2023, then soared by 91.64% to $1.6 million in 2024, then jumped by 1783.81% to $29.8 million in 2025, then plunged by 94.43% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $1.7 million in Q1 2026, $29.8 million in Q4 2025, and $30.8 million in Q3 2025.